Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 3/20 | 0.67 |
| ▸ | NRP1 | O14786 | 5/20 | 0.57 |
| ▸ | GRB2 | P62993 | 1/20 | 0.57 |
| ▸ | DPP4 | P27487 | 1/20 | 0.53 |
| ▸ | NTSR2 | O95665 | 7/20 | 0.52 |
| ▸ | NTSR1 | P30989 | 7/20 | 0.52 |
| ▸ | SORT1 | Q99523 | 5/20 | 0.52 |
| ▸ | PLG | P00747 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29886812 | 0.91 | F2 (0.55) | F2GRB2DPP4NTSR2NTSR1 | |
| SCHEMBL31519056 | 0.87 | F2 (0.58) | F2GRB2DPP4NTSR2NTSR1 | |
| SCHEMBL31114474 | 0.87 | F2 (0.53) | F2NRP1GRB2DPP4NTSR2 | |
| SCHEMBL29413028 | 0.86 | F2 (0.56) | F2GRB2DPP4NTSR2NTSR1 | |
| SCHEMBL29362706 | 0.86 | GRB2 (0.67) | F2NRP1GRB2NTSR2NTSR1 | |
| SCHEMBL1247726 | 0.86 | GRB2 (0.61) | F2NRP1GRB2NTSR2NTSR1 | |
| SCHEMBL30554061 | 0.86 | F2 (0.53) | F2GRB2DPP4NTSR2NTSR1 | |
| SCHEMBL31114279 | 0.85 | F2 (0.57) | F2NRP1GRB2DPP4NTSR2 | |
| SCHEMBL31746145 | 0.85 | OPRM1 (0.56) | F2DPP4NTSR2NTSR1SORT1 | |
| SCHEMBL29351044 | 0.85 | OPRM1 (0.54) | F2DPP4NTSR2NTSR1SORT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118480089-A | Gemini type surfactant-like antibacterial peptide resistant to enzymolysis, and preparation method and application thereof | 东北农业大学 | 2024-08-13 | — | — | CN | claimed |
| CN-116253782-B | Broad-spectrum antibacterial peptide KTR and application thereof | 浙江大学 | 2024-06-04 | — | — | CN | claimed |
| CN-116253782-A | Broad-spectrum antibacterial peptide KTR and application thereof | 浙江大学 | 2023-06-13 | — | — | CN | claimed |
| CN-115109772-A | Complex enzyme stabilizing system and complex enzyme containing same | 枣庄市妇幼保健院 | 2022-09-27 | — | — | CN | claimed |
| US-12590122-B2 | NRP-1 binding inhibitory peptides and uses thereof | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2026-03-31 | — | — | US | disclosed |
| US-20260014265-A1 | TRIPLE-PAYLOAD ANTIBODY-DRUG CONJUGATES (ADCs) | ARARIS BIOTECH AG (CH) | 2026-01-15 | — | — | US | disclosed |
| EP-3679062-B1 | T CELL RECEPTORS THAT BIND TO MIXED LINEAGE LEUKEMIA (MLL)-SPECIFIC PHOSPHOPEPTIDES AND METHODS OF USE THEREOF | MINK THERAPEUTICS INC (US) | 2025-11-19 | — | — | EP | disclosed |
| US-12391741-B2 | T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof | MINK THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250082774-A1 | PEPTIDE LINKERS COMPRISING TWO OR MORE PAYLOADS | ARARIS BIOTECH AG (CH) | 2025-03-13 | — | — | US | disclosed |
| EP-4482529-A1 | PEPTIDE LINKERS COMPRISING TWO OR MORE PAYLOADS | Araris Biotech AG (CH) | 2025-01-01 | — | — | EP | disclosed |
| US-12173084-B2 | Phosphorylated dicer antibody and methods of use thereof | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-12-24 | — | — | US | disclosed |
| CN-118742328-A | Peptide linker comprising two or more payloads | 阿拉里斯生物技术股份公司 | 2024-10-01 | — | — | CN | disclosed |
| CN-116034158-A | Engineered N-glycosyltransferases with altered specificity | 西北大学 | 2023-04-28 | — | — | CN | disclosed |
| CN-112760313-B | Complex enzyme stabilizing system and application thereof in cleaning of medical instruments | 枣庄市妇幼保健院 | 2022-10-28 | — | — | CN | disclosed |
| CN-115109772-A | Complex enzyme stabilizing system and complex enzyme containing same | 枣庄市妇幼保健院 | 2022-09-27 | — | — | CN | disclosed |
| WO-2022125673-A1 | CELL-PENETRATING PEPTIDES AND PEPTIDE COMPLEXES AND METHODS OF USE | FRED HUTCHINSON CANCER RESEARCH CENTER (US) | 2022-06-16 | — | — | WO | disclosed |
| US-20220169677-A1 | NRP-1 BINDING INHIBITORY PEPTIDES AND USES THEREOF | UNIVERSITÉ PARIS CITÉ (FR) | 2022-06-02 | — | — | US | disclosed |
| WO-2022091094-A2 | AGENTS BINDING MODIFIED ANTIGEN PRESENTED PEPTIDES AND USE OF SAME | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2022-05-05 | — | — | WO | disclosed |
| EP-3982991-A2 | NRP-1 BINDING INHIBITORY PEPTIDES AND USES THEREOF | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-04-20 | — | — | EP | disclosed |
| US-20220056155-A1 | PHOSPHORYLATED DICER ANTIBODY AND METHODS OF USE THEREOF | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014265-A1 | TRIPLE-PAYLOAD ANTIBODY-DRUG CONJUGATES (ADCs) | TOP2A, TOP1, TOP2B | F2 2366/4885NRP1 4767/4885GRB2 4859/4885 |
| US-12590122-B2 | NRP-1 binding inhibitory peptides and uses thereof | NRP1, FLT1, KDR | F2 3783/4885NRP1 1/4885GRB2 543/4885 |
| US-20250082774-A1 | PEPTIDE LINKERS COMPRISING TWO OR MORE PAYLOADS | DNPEP, VIP, LNPEP | F2 3389/4885NRP1 1497/4885GRB2 426/4885 |
| US-20220169677-A1 | NRP-1 BINDING INHIBITORY PEPTIDES AND USES THEREOF | NRP1, KDR, FLT1 | F2 4769/4885NRP1 1/4885GRB2 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.